← Leaderboards
Lishan Su
University Of North Carolina Chapel Hill
$24,513,865
Attributed
$34,165,846
Total exposure
21
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$34,165,846 · 21
By mechanism
R01$31,311,309 · 14
R21$2,491,409 · 6
R56$363,128 · 1
Top collaborators
- Rama Rao Amara6 shared
- Steven Edward Bosinger6 shared
- Alexander Ploss6 shared
- Yang-Xin Fu5 shared
- Stanley M Lemon5 shared
- Yue Xiong4 shared
- Raymond T Chung3 shared
- Shadi Salloum3 shared
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionIn VivoImmuneCellsPathogenesisHiv InfectionsHiv-1Immune ResponseMouse ModelNovel TherapeuticsBaseLiverHepatocyteImmune SystemChronicInflammationMediatingAnimal ModelT-LymphocyteSignal TransductionVirus ReplicationLiver DiseasesPreventHumanized Mouse
Grant awards (82)
YAP signaling in the pathogenesis of NAFLD in people living with HIV$812,743
R01 · FY2025 · DK
Tumor-associated pDC (TApDC) in liver cancer with HIV infection$634,061
R01 · FY2025 · CA · contact PI
YAP signaling in the pathogenesis of NAFLD in people living with HIV$780,234
R01 · FY2024 · DK
Preserving CTLA-4 immune checkpoint for safer and more effective cancer immunotherapy$513,119
R01 · FY2024 · AI · contact PI
YAP signaling in the pathogenesis of NAFLD in people living with HIV$829,042
R01 · FY2023 · DK
Preserving CTLA-4 immune checkpoint for safer and more effective cancer immunotherapy$513,119
R01 · FY2023 · AI · contact PI
Blocking type I interferon signaling to reverse T cell exhaustion and control HIV-1 reservoirs$814,022
R01 · FY2022 · AI · contact PI
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection$783,177
R01 · FY2022 · AI · contact PI
Preserving CTLA-4 immune checkpoint for safer and more effective cancer immunotherapy$513,119
R01 · FY2022 · AI · contact PI
Immune Mechanisms of Elevated Liver Diseases During HIV Infection$386,250
R01 · FY2022 · DK · contact PI
Blocking type I interferon signaling to reverse T cell exhaustion and control HIV-1 reservoirs$833,168
R01 · FY2021 · AI · contact PI
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection$783,177
R01 · FY2021 · AI · contact PI
Preserving CTLA-4 immune checkpoint for safer and more effective cancer immunotherapy$513,119
R01 · FY2021 · AI · contact PI
Immune Mechanisms of Elevated Liver Diseases During HIV Infection$386,250
R01 · FY2021 · DK · contact PI
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection$764,288
R01 · FY2020 · AI · contact PI
Preserving CTLA-4 immune checkpoint for safer and more effective cancer immunotherapy$540,369
R01 · FY2020 · AI · contact PI
Blocking type I interferon signaling to reverse T cell exhaustion and control HIV-1 reservoirs$539,240
R01 · FY2020 · AI · contact PI
Blocking type I interferon signaling to reverse T cell exhaustion and control HIV-1 reservoirs$311,116
R01 · FY2020 · AI · contact PI
HIV-1 Vpr disrupts the IFN-TET-ISG pathway to promote HIV-1 infection and persistence$288,640
R01 · FY2020 · AI · contact PI
Immune Mechanisms of Elevated Liver Diseases During HIV Infection$279,185
R01 · FY2020 · DK · contact PI
HIV-1 Vpr disrupts the IFN-TET-ISG pathway to promote HIV-1 infection and persistence$270,394
R01 · FY2020 · AI · contact PI
Immune Mechanisms of Elevated Liver Diseases During HIV Infection$106,346
R01 · FY2020 · DK · contact PI
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection$30,549
R01 · FY2020 · AI · contact PI
Blocking type I interferon signaling to reverse T cell exhaustion and control HIV-1 reservoirs$842,342
R01 · FY2019 · AI · contact PI
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection$783,487
R01 · FY2019 · AI · contact PI
HIV-1 Vpr disrupts the IFN-TET-ISG pathway to promote HIV-1 infection and persistence$532,000
R01 · FY2019 · AI · contact PI
Immune Mechanisms of Elevated Liver Diseases During HIV Infection$388,750
R01 · FY2019 · DK · contact PI
Blocking type I interferon signaling to reverse T cell exhaustion and control HIV-1 reservoirs$862,217
R01 · FY2018 · AI · contact PI
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection$797,362
R01 · FY2018 · AI · contact PI
HIV-1 Vpr disrupts the IFN-TET-ISG pathway to promote HIV-1 infection and persistence$532,000
R01 · FY2018 · AI · contact PI
Immune Mechanisms of Elevated Liver Diseases During HIV Infection$388,750
R01 · FY2018 · DK · contact PI
HIV-1 Vpr disrupts the IFN-TET-ISG pathway to promote HIV-1 infection and persistence$532,000
R01 · FY2017 · AI · contact PI
HIV-1 Vpr disrupts the IFN-TET-ISG pathway to promote HIV-1 infection and persistence$532,000
R01 · FY2016 · AI · contact PI
Novel therapeutic approaches to treating chronic hepatitis B virus infection$486,852
R01 · FY2016 · DK · contact PI
Murine Model of HCV-Associated Human Liver Cancer$470,695
R01 · FY2016 · CA
HIV co-infection and HCV-induced liver fibrosis in vivo$370,000
R01 · FY2016 · AI · contact PI
Novel therapeutic approaches to treating chronic hepatitis B virus infection$551,970
R01 · FY2015 · DK · contact PI
Murine Model of HCV-Associated Human Liver Cancer$470,695
R01 · FY2015 · CA
HIV co-infection and HCV-induced liver fibrosis in vivo$370,000
R01 · FY2015 · AI · contact PI
Novel therapeutic approaches to treating chronic hepatitis B virus infection$486,852
R01 · FY2014 · DK · contact PI
Murine Model of HCV-Associated Human Liver Cancer$456,574
R01 · FY2014 · CA
HIV co-infection and HCV-induced liver fibrosis in vivo$370,000
R01 · FY2014 · AI · contact PI
Novel therapeutic approaches to treating chronic hepatitis B virus infection$65,118
R01 · FY2014 · DK · contact PI
Novel therapeutic approaches to treating chronic hepatitis B virus infection$499,852
R01 · FY2013 · DK · contact PI
Murine Model of HCV-Associated Human Liver Cancer$442,453
R01 · FY2013 · CA
HIV co-infection and HCV-induced liver fibrosis in vivo$347,800
R01 · FY2013 · AI · contact PI
Murine Model of HCV-Associated Human Liver Cancer$470,695
R01 · FY2012 · CA
HIV co-infection and HCV-induced liver fibrosis in vivo$370,000
R01 · FY2012 · AI · contact PI
HIV-1 Replication and Pathogenesis in vivo$366,300
R01 · FY2012 · AI · contact PI
HIV-1 Replication and Pathogenesis in vivo$366,300
R01 · FY2011 · AI · contact PI
Treg in HIV-1 Replication and Pathogenesis$361,058
R01 · FY2011 · AI · contact PI
Treg in HIV-1 Replication and Pathogenesis$364,705
R01 · FY2010 · AI · contact PI
HIV-1 Replication and Pathogenesis in vivo$359,361
R01 · FY2010 · AI · contact PI
Ethanol and HBV Infection on HCC Development in A Novel Humanized Mouse Model$204,668
R21 · FY2010 · AA · contact PI
Pathogenesis of HCV in a Novel Mouse Model$185,000
R21 · FY2010 · AI · contact PI
Treg in HIV-1 Replication and Pathogenesis$368,286
R01 · FY2009 · AI · contact PI
HIV-1 Replication and Pathogenesis in vivo$352,192
R01 · FY2009 · AI · contact PI
Pathogenesis of HCV in a Novel Mouse Model$216,218
R21 · FY2009 · AI · contact PI
A Novel Humanized Mouse Model for Studying HIV/HCV Co-Infection and Liver Disease$211,206
R21 · FY2009 · AA · contact PI
Ethanol and HBV Infection on HCC Development in A Novel Humanized Mouse Model$200,550
R21 · FY2009 · AA · contact PI
Treg in HIV-1 Replication and Pathogenesis$366,848
R01 · FY2008 · AI · contact PI
A Novel Humanized Mouse Model for Studying HIV/HCV Co-Infection and Liver Disease$173,738
R21 · FY2008 · AA · contact PI
Modulation of HIV-1 Replication and T Cell Activation by FoxP3$363,128
R56 · FY2007 · AI · contact PI
HIV-1 Replication and Pathogenesis in the Human Thymus$342,335
R01 · FY2007 · AI · contact PI
HIV-1 Replication and Pathogenesis in the Human Thymus$352,559
R01 · FY2006 · AI · contact PI
HIV-1 Replication and Pathogenesis in the Human Thymus$361,044
R01 · FY2005 · AI
HIV-1 Replication and Pathogenesis in the Human Thymus$361,044
R01 · FY2004 · AI
RHOA EFFECTOR IN HIV-1 REPLICATION AND PATHOGENESIS$325,837
R01 · FY2004 · AI
Novel genetic approach to dissecting homing /engraftment$216,897
R21 · FY2004 · HL
HIV-1 Replication and Pathogenesis in the Human Thymus$361,044
R01 · FY2003 · AI
RHOA EFFECTOR IN HIV-1 REPLICATION AND PATHOGENESIS$325,837
R01 · FY2003 · AI
Novel genetic approach to dissecting homing /engraftment$216,897
R21 · FY2003 · HL
Genetic Analy. of Chemokine Receptors in T Cell Develop.$180,522
R21 · FY2003 · AI
Evolution of HIV-1 in genetically humanized mouse models$144,147
R21 · FY2003 · CA
RHOA EFFECTOR IN HIV-1 REPLICATION AND PATHOGENESIS$276,962
R01 · FY2002 · AI
Novel genetic approach to dissecting homing /engraftment$216,897
R21 · FY2002 · HL
Genetic Analy. of Chemokine Receptors in T Cell Develop.$180,522
R21 · FY2002 · AI
Evolution of HIV-1 in genetically humanized mouse models$144,147
R21 · FY2002 · CA
RHOA EFFECTOR IN HIV-1 REPLICATION AND PATHOGENESIS$325,837
R01 · FY2001 · AI
HIV-1 PATHOGENESIS IN THE HUMAN THYMUS$204,810
R01 · FY2001 · AI
RHOA EFFECTOR IN HIV-1 REPLICATION AND PATHOGENESIS$324,913
R01 · FY2000 · AI
HIV-1 PATHOGENESIS IN THE HUMAN THYMUS$198,846
R01 · FY2000 · AI